372 filings
6-K
BDRX
Biodexa Pharmaceuticals Plc
19 Apr 24
Preliminary Results for the Year Ended 31 December 2023
8:19am
424B3
BDRX
Biodexa Pharmaceuticals Plc
28 Mar 24
Prospectus supplement
6:00am
EFFECT
BDRX
Biodexa Pharmaceuticals Plc
28 Mar 24
Notice of effectiveness
12:15am
F-1
BDRX
Biodexa Pharmaceuticals Plc
18 Mar 24
Registration statement (foreign)
4:31pm
424B3
ehlmc163vx28j o52v4
28 Feb 24
Prospectus supplement
4:15pm
424B3
ztkodmj4428a4ztf
28 Feb 24
Prospectus supplement
4:15pm
424B3
vm64qtr4pa7cw0 hd
28 Feb 24
Prospectus supplement
4:14pm
6-K
eju lua5s07m5zdg73r
23 Feb 24
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
1:25pm
6-K
4wsqvgstp
22 Jan 24
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
8:51am
D
w0at9i5jnz4
3 Jan 24
$6.79 mm in equity / options / securities to be acquired, sold $6.79 mm, 1 investor
7:01pm
6-K
2xi 0zs0os
29 Dec 23
Biodexa Appoints Ann Merchant to the Board of Directors
12:10pm
424B3
593j3hahh 4p
26 Dec 23
Prospectus supplement
4:53pm
424B3
m18y qeijbcr1jd
26 Dec 23
Prospectus supplement
4:53pm
424B3
xi4uv2820xj7rodz9b4c
26 Dec 23
Prospectus supplement
4:51pm
6-K
0znat1w453471nyi9x5n
21 Dec 23
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
4:30pm
424B4
6v04 hh1039el20gl9
20 Dec 23
Prospectus supplement with pricing info
4:54pm
EFFECT
hihy2smh 73
19 Dec 23
Notice of effectiveness
12:15am
CORRESP
ceama40xabwbg
15 Dec 23
Correspondence with SEC
12:00am
CORRESP
odcyb7w8pv7 fy8t12e
15 Dec 23
Correspondence with SEC
12:00am